Advancement of artificial intelligence in digital pathology: from exploratory end point to primary end point in non-alcoholic steatohepatitis clinical trials

被引：0
|
作者：
Tai, Dean [1 ]
Akbary, Kutbuddin [1 ]
Ren, Yayun [1 ]
Chng, Elaine [1 ]
机构：
[1] HistoIndex Pte Ltd, Clin Res, Singapore, Singapore
来源：
JOURNAL OF HEPATOLOGY | 2023年 / 78卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
WED-237
引用
收藏
页码：S334 / S334
页数：1
相关论文
共 35 条
  • [31] Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: Individual patient data from 20,898 patients on 18 randomized trials
    Sargent, DJ
    Wieand, HS
    Haller, DG
    Gray, R
    Benedetti, JK
    Buyse, M
    Labianca, R
    Seitz, JF
    O'Callaghan, CJ
    Francini, G
    Grothey, A
    O'Connell, M
    Catalano, PJ
    Blanke, CD
    Kerr, D
    Green, E
    Wolmark, N
    Andre, T
    Goldberg, RM
    De Gramont, A
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (34) : 8664 - 8670
  • [32] Should disease free survival (DFS) be used as a surrogate end-point in adjuvant chemotherapy trials for non-small-cell lung cancer (NSCLC)? Analysis of 7 randomized clinical trials (RCTS) exploring platinum-based chemotherapy
    Bria, Emilio
    Cecere, Fabiana Letizia
    Cuppone, Federica
    Nistico, Cecilia
    Milella, Michele
    Facciolo, Francesco
    Sperduti, Isabella
    Ceribelli, Anna
    Terzoli, Edmondo
    Cognetti, Francesco
    Giannarelli, Diana
    ANNALS OF ONCOLOGY, 2007, 18 : 34 - 34
  • [33] Is overall survival a realistic primary end point in advanced colorectal cancer studies? A critical assessment based on four clinical trials comparing fluorouracil plus leucovorin with the same treatment combined either with oxaliplatin or with CPT-11
    Di Leo, A
    Buyse, M
    Bleiberg, H
    ANNALS OF ONCOLOGY, 2004, 15 (04) : 545 - 549
  • [34] Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052)
    O'Brien, Mary E. R.
    Gaafar, Rabab M.
    Popat, Sanjay
    Grossi, Francesco
    Price, Allan
    Talbot, Denis C.
    Cufer, Tanja
    Ottensmeier, Christian
    Danson, Sarah
    Pallis, Athanasios
    Hasan, Baktiar
    Van Meerbeeck, Jan P.
    Baas, Paul
    EUROPEAN JOURNAL OF CANCER, 2013, 49 (13) : 2815 - 2822
  • [35] Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: Data from 129676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803
    Sargent, D.
    Shi, Q.
    Yothers, G.
    Van Cutsem, E.
    Cassidy, J.
    Saltz, L.
    Wolmark, N.
    Bot, B.
    Grothey, A.
    Buyse, M.
    de Gramont, A.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 (07) : 990 - 996
1234